Abstract:Janus kinase 2(JAK2) is a potential target for anticancer drugs in the treatment of numerous myeloproliferative diseases due to its central role in the JAK/STAT signaling cascade. In this study, the binding behavior of 2 amino-pyridine derivatives as JAK2 inhibitors was investigated by using multifaceted strategies including 3D-QSAR, molecular docking, Fingerprint analysis, MD simulations, and MM-PBSA calculations. A credible COMFA (q2 = 0.606 and r2 = 0.919) and COMSIA (q2 = 0.641 and r2 = 0.992) model was developed, where the internal and external validation revealed that the obtained 3D-QSAR models could be capable of predicting bioactivities of JAK2 inhibitors. The structural criteria provided by the contour maps of model were used to computationally develop more potent 100 new JAK2 inhibitors. Docking studies were conducted on the model data set and newly developed compounds (in-house library) to demonstrate their binding mechanism and highlight the key interacting residues within JAK2 active site. The selected docked complexes underwent MD simulation (100 ns), which contributed in the further study of the binding interactions. Binding free energy analyses (MMGB/PBSA) revealed that key residues such as Glu930, Leu932 (hinge region), Asp939 (solvent accessible region), Arg980, Asn981and Asp994 (catalytic site) have a significantly facilitate ligand-protein interactions through H-bonding and van der Waals interactions. The preliminary in-silico ADMET evaluation revealed encouraging results for all the modeled and in-house library compounds. The findings of this research have the potential to offer valuable recommendations for the advancement of novel, potent, and efficacious JAK2 inhibitors. Overall, this work has successfully employed a wide range of computer-based methodologies to understand the interaction dynamics between 2-amino-pyridine derivatives and the JAK2 enzyme, which is a crucial target in myeloproliferative disorders.Communicated by Ramaswamy H. Sarma.

Advances in the design and discovery of next-generation janus kinase-2 (JAK2) inhibitors for the treatment of myeloproliferative neoplasms

JAK2 inhibitors for the treatment of Philadelphia-negative myeloproliferative neoplasms: current status and future directions

Advances in the Research of JAK2 Abnormalities in Heamatological Disorders

Janus kinase 2 inhibitors in myeloproliferative disorders

Combination of ligand‐based and structure‐based virtual screening for the discovery of novel Janus kinase 2 inhibitors against philadelphia-negative myeloproliferative neoplasms

New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms

[Inhibitors of JAK2/STAT Signaling Pathway and Hematologic Malignancies-Review].

Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms

Experimental therapeutics for patients with myeloproliferative neoplasias

A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases

Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity

Roles of Germline JAK2 Activation Mutation JAK2 V625F in the Pathology of Myeloproliferative Neoplasms

Research progress of JAK1/2 inhibitors in the treatment of myeloproliferative neoplasms

Biological Evaluations and Computer-Aided Approaches of Janus Kinases 2 and 3 Inhibitors for Cancer Treatment: A Review

Discovery and optimization of 2-aminopyridine derivatives as novel and selective JAK2 inhibitors.

Molecular modeling of novel 2-aminopyridine derivatives as potential JAK2 inhibitors: a rational strategy for promising anticancer agents

[Progress of Study on JAK2V617F Mutation in Myeloproliferative Neoplasm].

Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms

Dual-target Janus Kinase (JAK) Inhibitors: Comprehensive Review on the JAK-based Strategies for Treating Solid or Hematological Malignancies and Immune-Related Diseases.

Janus Kinases (jaks): the Efficient Therapeutic Targets for Autoimmune Diseases and Myeloproliferative Disorders.

Recent Progress in the Studies on Structure and Function of JAK2